跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
OPDUALAG
Authorized
STANDARD
OPDUALAG
bristol-myers squibb canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
65a768d24c6e9cfa
Company
bristol-myers squibb canada
Type
Standard
Approval Details
Approval Id
65a768d24c6e9cfa
Drug Approval Canada Name
OPDUALAG
Product Name
OPDUALAG
Status
Marketed
Status Date
2024-02-12
Original Market Date
2024-02-12
Din
02541416
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FY02 NIVOLUMAB AND RELATLIMAB
Atc Name
l 01 fy 02
Aig Number
0264981001
Company Name
bristol-myers squibb canada
Company Address
2344 Boul. Alfred-Nobel, Suite 300, St-Laurent, Quebec, Canada, H4S 0A4
Active Ingredients
NIVOLUMAB
240 MG / 20 ML
RELATLIMAB
80 MG / 20 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
65a768d24c6e9cfa
Type
Standard
Back to Health Canada Approvals
OPDUALAG - Health Canada Drug Approval Details